CompletedNCT01466439
This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand what a digital app or remote support tool can reveal about signals in the brain or body that may guide care later on.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- France
- Sponsor
- University Hospital, Caen
- Condition
- Schizophrenia
CompletedNCT07137572
This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand whether a digital app or remote support tool can make support easier to access outside standard clinic visits.
SchizophreniaOtherOver 18 Years
- Countries
- Greece
- Sponsor
- KAVADIA ELENI
- Condition
- Schizophrenia
CompletedNCT07452835
This study exists to understand how this type of care holds up over time after the earliest research stage. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.
DepressionOtherFrom 16 Years to 65 Years
- Countries
- Egypt
- Sponsor
- Menoufia University
- Condition
- Depression
CompletedNCT04324944
This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.
SchizophreniaOtherOver 18 Years
- Countries
- United States
- Sponsor
- VA Office of Research and Development
- Condition
- Schizophrenia
RecruitingNCT06929442
This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand what this type of care could change in day-to-day care and decision-making.
SchizophreniaOtherFrom 18 Years to 30 Years
- Countries
- United States
- Sponsor
- Massachusetts General Hospital
- Condition
- Schizophrenia
CompletedNCT04395157
This study exists to explore whether a digital app or remote support tool could improve care and understanding. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
AnxietyOtherOver 18 Years
- Countries
- United States
- Sponsor
- VA Office of Research and Development
- Condition
- Anxiety
RecruitingNCT06774430
This study exists to see whether a digital app or remote support tool can make care clearer and more responsive. Researchers are trying to understand whether a digital app or remote support tool can make support easier to access outside standard clinic visits.
SchizophreniaOtherFrom 12 Years to 29 Years
- Countries
- United States
- Sponsor
- Columbia University
- Condition
- Schizophrenia
CompletedNCT05145413
This study exists to compare options and see whether a medication treatment offers something meaningfully different. Researchers are trying to understand what a medication treatment could change in day-to-day care and decision-making.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Bulgaria, India, Japan, Poland, Romania, Serbia, United Kingdom, United States
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Condition
- Schizophrenia
RecruitingNCT07565428
This study exists to understand whether a medication treatment is both safe enough and useful enough to take further. Researchers are trying to understand whether a medication treatment can better prevent setbacks and support longer-term stability.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- Minerva Neurosciences
- Condition
- Schizophrenia
CompletedNCT00001247
This study exists to see whether a digital app or remote support tool can make care clearer and more responsive. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 120 Years
- Countries
- United States
- Sponsor
- National Institute of Mental Health (NIMH)
- Condition
- Schizophrenia
CompletedNCT05562674
This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can make support easier to access outside standard clinic visits.
SchizophreniaOtherOver 18 Years
- Countries
- United States
- Sponsor
- VA Office of Research and Development
- Condition
- Schizophrenia
CompletedNCT00024622
This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand what a digital app or remote support tool can reveal about signals in the brain or body that may guide care later on.
SchizophreniaOtherFrom 18 Years to 90 Years
- Countries
- United States
- Sponsor
- National Institute of Mental Health (NIMH)
- Condition
- Schizophrenia
CompletedNCT06175559
This study exists to understand what helps cognitive behavioural therapy, a structured talking treatment, work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether cognitive behavioural therapy, a structured talking treatment, can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- China
- Sponsor
- Zhu Dian
- Condition
- Schizophrenia
RecruitingNCT07559084
This study exists to compare options and see whether brain scans or other body measurements offers something meaningfully different. Researchers are trying to understand whether brain scans or other body measurements can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 16 Years to 45 Years
- Countries
- China
- Sponsor
- Shanghai Mental Health Center
- Condition
- Schizophrenia
CompletedNCT03055338
This study exists to understand how the medication Elpipodect holds up over time after the earliest research stage. Researchers are trying to understand whether the medication Elpipodect can give earlier or clearer feedback during care.
SchizophreniaOtherFrom 18 Years to 50 Years
- Countries
- United States
- Sponsor
- Merck Sharp & Dohme LLC
- Condition
- Schizophrenia
CompletedNCT04506905
This study exists to better understand the safety of the medication Elpipodect and how manageable it feels in practice. Researchers are trying to understand how people respond to the medication Elpipodect in practice and what may need to be adjusted.
SchizophreniaOtherFrom 18 Years to 80 Years
- Countries
- United States
- Sponsor
- Merck Sharp & Dohme LLC
- Condition
- Schizophrenia
RecruitingNCT07557381
This study exists to see whether a therapy or guided support program is workable and worth testing more broadly. Researchers are trying to understand whether a therapy or guided support program can better support energy, concentration, and everyday functioning.
SchizophreniaOtherFrom 18 Years to 45 Years
- Countries
- China
- Sponsor
- Shanghai Mental Health Center
- Condition
- Schizophrenia
CompletedNCT02181803
This study exists to better understand the safety of the medication MK-8189 and how manageable it feels in practice. Researchers are trying to understand how people respond to the medication MK-8189 in practice and what may need to be adjusted.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- Global
- Sponsor
- Merck Sharp & Dohme LLC
- Condition
- Schizophrenia
Not Yet RecruitingNCT07555275
This study exists to understand what helps smoking support or smoking-related treatment work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether smoking support or smoking-related treatment can give earlier or clearer feedback during care.
SchizophreniaOtherOver 18 Years
- Countries
- United States
- Sponsor
- VA Office of Research and Development
- Condition
- Schizophrenia
CompletedNCT05406440
This study exists to better understand the safety of the medication Elpipodect and how manageable it feels in practice. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- Merck Sharp & Dohme LLC
- Condition
- Schizophrenia
RecruitingNCT07557368
This study exists to understand how psychoeducation, a guided learning and support program, holds up over time after the earliest research stage. Researchers are trying to understand whether psychoeducation, a guided learning and support program, can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 45 Years
- Countries
- China
- Sponsor
- Shanghai Mental Health Center
- Condition
- Schizophrenia
CompletedNCT04624243
This study exists to see whether the medication MK-8189 can play a useful role in care. Researchers are trying to understand how people respond to the medication MK-8189 in practice and what may need to be adjusted.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- Bulgaria, Croatia, Japan, Latvia, Poland, Romania, Russian Federation, Serbia, South Korea, Taiwan, Ukraine, United States
- Sponsor
- Merck Sharp & Dohme LLC
- Condition
- Schizophrenia
CompletedNCT00001258
This study exists to explore whether blood tests and biological markers could improve care and understanding. Researchers are trying to understand whether blood tests and biological markers can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 90 Years
- Countries
- United States
- Sponsor
- National Institute of Mental Health (NIMH)
- Condition
- Schizophrenia
SuspendedNCT05046353
This study exists to understand what helps a medication treatment work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether a medication treatment can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 50 Years
- Countries
- United States
- Sponsor
- New York State Psychiatric Institute
- Condition
- Schizophrenia
CompletedNCT05893862
This study exists to better understand the safety of the medication MK-8189 and how manageable it feels in practice. Researchers are trying to understand how people respond to the medication MK-8189 in practice and what may need to be adjusted.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- United States
- Sponsor
- Merck Sharp & Dohme LLC
- Condition
- Schizophrenia